Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02029989 · ClinicalTrials.gov registry record · NA

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

A NA study, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
121
Enrollment target

NCT02029989: Completed NA study, sponsored by University of Minnesota.

NCT02029989 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02029989, a NA study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
121 participants
Enrollment target

Study Summary

The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication management (CMM) pharmacist interventions or a Usual Treatment Group (UTG) receiving no CMM interventions. All subjects were recruited from three community mental health clinic settings in Minnesota.

Primary Outcome

compare test results in subjects between the PCS and NCS groups, with or without pre-existing MetS and/or related metabolic conditions at baseline

Interventions

  • DEVICE Glucose and lipids
  • DEVICE Glycosylated Hemoglobin A1c
  • DEVICE Blood Pressure and Heart Rate
  • DEVICE Body mass index
  • DEVICE Waist and Hip circumference

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2010-02
Est. Completion 2012-02
Phase NA
University of Minnesota

966 total trials

What the finished NCT02029989 record still lists

NCT02029989 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 5 interventions - of which Glucose and lipids is the first listed.

NCT02029989 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02029989 about?

NCT02029989 is a clinical study titled "Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness". The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication ...

What is the current status of trial NCT02029989?

This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2010-02. Estimated completion is 2012-02.

What interventions are being tested in trial NCT02029989?

The interventions under investigation include: Glucose and lipids (DEVICE), Glycosylated Hemoglobin A1c (DEVICE), Blood Pressure and Heart Rate (DEVICE), Body mass index (DEVICE), Waist and Hip circumference (DEVICE).

Who is sponsoring clinical trial NCT02029989?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02029989's enrollment target sits among peer trials

121 762nd of 2000 higher than 1,239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02029989, the US trial registry maintained by the National Library of Medicine. NCT02029989 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.